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INTRODUCTION
Gastrointestinal stromal tumors (GIST) are rare mesenchymal
neoplasms of the digestive tract (1-3). Most GIST are initiated by
oncogenic mutations involving the receptor tyrosine kinase proto-
oncogene c-kit gene or the platelet -derived growth factor receptor
alpha (PDGFRA) gene (4). The synchronous occurrence of GIST
and other primary gastrointestinal malignancies has been reported
previously (5-13). However, the synchronous occurrence of lung
cancer and GIST seems to be extremely rare (6-8). We experi-
enced a case of advanced stage pulmonary adenocarcinoma associ-
ated with a rectal GIST. Epidermal growth factor receptor (EGFR)
and c-kit gene mutations were identified in the pulmonary adeno-
carcinoma and GIST, respectively. To the best of our knowledge,
this is the first report about the treatment of lung cancer and GIST
via the alternating administration of two kinds of molecular target-
ing drugs.
CASE REPORT
An 83-year-old woman was admitted to a local clinic because of
lower abdominal pain. As an abnormal rectal mass was observed
on abdominal computed tomography (CT), she was referred to our
hospital. A physical examination produced unremarkable results,
and no superficial lymph node swelling was detected. Abdominal
CT revealed an abnormal mass in the ventral rectum (Fig. 1A, B).
Colon fiberscopy was performed, and the abdominal mass was
found to be a rectal submucosal tumor (Fig. 2). An ultrasound-
guided needle biopsy of the rectal submucosal tumor was per-
formed via the perineum. A histological examination indicated that
the lesion was predominantly composed of spindle-shaped cells,
which were found to be diffusely positive for c-kit in a subsequent
immunohistochemical analysis (Fig. 3A, B). In addition, a c-kit
gene mutation (exon 11 deletion) was also detected in the speci-
men. The patient’s laboratory findings on admission included a
hemoglobin level of 10.7 g/dL, a carcinoembryonic antigen (CEA)
level of 3.5 ng/mg, and a cancer antigen 19-9 (CA19-9) level of
5.0 U/ml. The patient did not exhibit severe anemia or elevated
tumor marker levels. The possibility of rectal resection had been
mentioned to the patient and her relatives, but they did not want
to take this option. The patient and her relatives understood that
if the tumor increased in size then the patient might develop ileus
and that this would require a colostomy to be performed. The pa-
tient was treated with imatinib (400 mg/day, orally), but the dose
of imatinib was reduced after one week (300 mg/day, orally) as
the patient suffered severe nausea and diarrhea. After that, the
patient’s side effects improved. An abdominal CT scan performed
at one month after the start of treatment showed that the patient’s
abnormal findings had improved (a partial response (PR) accord-
ing to the RECIST criteria), and chest and abdominal CT scans
performed at three months after the start of treatment indicated
that the patient’s abnormal findings continued to exhibit a PR, but
left -sided pleural effusion was detected (Fig. 4A, B). As the patient
complained of dyspnea, she underwent a thoracic cavity puncture,
and a cytological examination revealed an adenocarcinoma, which
was positive for an EGFR mutation (exon 19 deletion) (Fig. 5). A
chest CT scan performed after the pleural effusion had been
drained revealed a tumor (diameter : 2220 mm) in the left lower
lobe (Fig. 4C). The patient did not wish to undergo 18F- fluorodeoxy
glucose positron emission tomography. Brain magnetic resonance
imaging did not detect any metastases. As a result, the patient
was diagnosed with synchronous pulmonary adenocarcinoma
(T1bNxM1a, Stage IV) and GIST (high risk).
Although it was necessary to treat both the patient’s lung cancer
and GIST, it was considered that administering both erlotinib (for
the lung tumor) and imatinib (for the GIST) simultaneously would
result in strong side effects. Thus, we decided to administer them
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alternately. As we considered that the patient’s lung cancer was
more serious than her GIST, we decided to administer the lung
cancer treatment for longer periods than the GIST treatment. The
patient was treated with imatinib for two weeks (300 mg/day,
orally) and erlotinib (100 mg/day, orally) for four weeks in an al-
ternating manner. Since side effects were expected, erlotinib was
administered at a reduced dose from the beginning. The only side
effect of this treatment was a mild rash (Grade 1). Good control
of the lung cancer and the GIST was achieved (Fig. 6A, B), and the
patient’s CEA level fell from 6.6 ng/ml to 3.3 ng/ml. The patient
demonstrated a PR according to the RECIST criteria, but passed
away two years after the start of therapy at another hospital. The
patient’s lung cancer and rectal GIST did not worsen at the other
hospital. The patient died of a urinary tract infection, but the above-
mentioned therapy improved her quality of life (QOL) during the
two-year treatment period.
Figure 1. An abdominal CT scan detected a tumor in the ventral rectum (arrows).
A : axial view, B : coronal view
Figure 2. Colon fiberscopy showed a tumor in the rectal submucosa
Figure 3. A histological analysis demonstrated the dense proliferation of spindle -shaped cells (A : Hematoxylin and eosin (HE) staining400)
The positive immunohistochemical staining ofc -kit (CD117) was consistent with a diagnosis of GIST (B :400).




This case highlighted two important clinical issues : 1) There
have only been a few reports about synchronous cases of GIST and
lung cancer ; and 2) the administration of two kinds of molecular
targeting drugs in an alternating manner brought both the lung
cancer and GIST under control.
Regarding the first issue, GIST is a rare neoplasm that represents
about 0.1 -1.0% of all malignant neoplasms of the gastrointestinal
tract. Most GIST arise from the stomach (50-62%), small intestine
(20-30%), colon (11%), or rectum (7%), while the esophagus is rarely
affected (0.6-1%) (3, 11, 19, 20). GIST have been reported to occur
synchronously, mostly with gastrointestinal carcinomas (21), but
there are few reports about them occurring synchronously with
lung cancer. Herein, we reported a case of synchronous pulmonary
adenocarcinoma and GIST. The lung cancer was found incidentally
during the treatment of the GIST with imatinib. The malignant cells
in both tumors had specific gene mutations. Synchronous and
asynchronous cases of GIST and other malignancies have been
studied in several case series (5-12). Based on these reports, GIST
associated with other primary malignancies occur at incidence
rates ranging from 2.9% to 32.6%. The most common accompanying
neoplasms are colorectal and gastric adenocarcinoma, and pan-
creatic tumors (5, 9, 10). Therefore, cases in which GIST occur
synchronously or asynchronously with other gastrointestinal ma-
lignancies are relatively common. The high prevalence of other
gastrointestinal malignancies in GIST patients is probably due to
the frequent use of investigative or therapeutic surgery to treat/
investigate other malignancies. Concomitant GIST are thus usually
discovered incidentally during surgery performed for other malig-
nancies. Indeed, Kawanowa et al. (11) reported that microscopic
GIST were found in 35% of gastric cancer patients that underwent
stomach resections. However, synchronous GIST have rarely been
detected in patients with lung cancer. Pandurengan et al. (6) sum-
marized the clinical courses of 783 GIST patients and found only
10 cases in which lung cancer (1.3%) occurred before or after the
GIST. Agaimy et al. (12) reported that lung cancer exhibited a fre-
quency of 5% (26 cases) in GIST patients (486 cases). Furthermore,
Figure 4. Patient’s CT findings at 3 months after the start of treatment
A : An abdominal CT scan revealed that the patient’s abnormal findings had improved slightly after 3 months’ imatinib therapy (arrow). B : A chest
CT scan detected left -sided pleural effusion. C : Chest CT detected a tumor in the left lower lobe after pleural effusion drainage (arrowhead).
Figure 5. A cytological analysis resulted in a diagnosis of pulmonary
adenocarcinoma (100)
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Ponti et al. (7) and Ruka et al. (13) summarized 141 and 180 cases
of GIST, respectively, and identified one and two patients, respec-
tively, that developed non-small cell lung cancer after being diag-
nosed with GIST. Therefore, the development of lung cancer in
patients with GIST is not necessarily rare.
As for the second issue, in the present case two kinds of molecu-
lar targeting drugs were administered in an alternating manner to
treat the patient’s lung cancer and GIST, and these treatments
were effective at bringing the tumors under control. The patient
was treated with imatinib for two weeks and erlotinib for four weeks
on an alternating basis. In the present case, we determined the
optimal treatment strategy based on the expected side effects. The
patient was initially treated with imatinib (400 mg/day, orally), but
the dose was subsequently reduced to 300 mg/day (orally) since
severe nausea and diarrhea appeared. After that, the patient’s side
effects improved. Since side effects were expected, erlotinib was
administered at a reduced dose from the beginning. Although it
was necessary to treat both the patient’s lung cancer and GIST,
it was considered that administering both drugs at the same time
would result in strong side effects. Therefore, we decided to admin-
ister them alternately. As we considered that the patient’s lung
cancer was more serious than her GIST, we administered erlotinib
for longer periods than imatinib. Good control of both the lung can-
cer and the GIST was achieved (the patient exhibited a PR accord-
ing to the RECIST criteria), but the patient died of a urinary tract
infection at two years after the start of therapy. Despite this, no pleu-
ral effusion or ileus occurred, which would have been indicative of
the progression of the lung cancer and GIST, respectively, and the
patient did not develop any treatment-related side effects. In addi-
tion, the abovementioned therapy improved the patient’s QOL dur-
ing the two-year treatment period.
We found an EGFR mutation in the pulmonary adenocarcinoma
and c-kit mutation in the GIST in the present case. The detection
of these gene mutations helped us to select treatment strategies
involving molecular targeting agents that would have beneficial
clinical effects on both tumors. The patient was initially treated with
imatinib and erlotinib. Previous studies have attempted to detect
EGFR and c-kit mutations in biphasic malignant lung tumors com-
posed of primitive mesenchymal and epithelial components (17,
18). However, no coexisting mutations were found in these studies
(17, 18). In the present case, the EGFR mutation status of the GIST
and the c-kit mutation status of the lung tumor were not analyzed. It
is therefore difficult to speculate on the interactions between the
EGFR and c-kit gene mutations and their etiological effects in the
present case. Although the oncogenic interactions between the
detected mutations remain to be determined, the coexistence of
two different malignancies harboring specific EGFR and c-kit mu-
tations in a single patient might represent useful information for
future studies.
In summary, the present case is not only of interest due to the
rare co-occurrence of a GIST and lung cancer, but also because
it involved two tumors carrying different gene mutations, and both
tumors were brought under control using different molecular tar-
geting drugs.
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